Definiens XD framework will be used to build on ACD’s RNAscope biomarker analysis and diagnostics platform.
Definiens will develop an image analysis application for Advanced Cell Diagnostics (ACD) that will automatically process and analyze images from assays carried out through ACD’s RNAscope biomarker analysis and diagnostics platform.
The partnership will build on Definiens software, based on the Definiens XD framework, as well as on ACD’s RNAscope, a multiplex fluorescent and chromogenic in situ hybridization platform. Definiens XD is designed to offer users accurate, robust, and scalable image analysis solutions for a range of histology analysis applications, says the firm.RNAscope is designed to detect and quantify RNA biomarkers in situ at single molecule sensitivity in individual cells in all major biological specimen types including cell lines, PBMC, and FFPE tissue sections.
“This advanced image analysis solution will bring objective and accurate quantification to RNAscope and enable a new generation of diagnostic applications such as circulating tumor cell detection and molecular analysis,” says Yuling Luo, Ph.D., ACD’s founder, president, and CEO.